NetScientific: refinanced and focused on enhancing value

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

NetScientic PLC said its subsidiary ProAxis Ltd has won approval for a key US patent for technology that can be used to screen, identify and monitor people at risk of bone disease.

The company said the patent for its K-POSTN Assay, which it intends to launch shortly, is a significant step towards measuring bone health for patients at high risk of osteoporotic fractures.

ProAxsis is working with the expert Bone Health team led by Professor Serge () at the University of Geneva to create a novel and patented bone-specific enzyme-linked immunoassay (ELISA) for the detection of serum K-POSTN, which can be used to predict fractures in post-menopausal women.

Dr David Ribeiro, CEO of ProAxsis, commented: “The K-POSTN assay has the potential to help healthcare professionals screen, identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases, thus enabling early therapeutic intervention which will decrease the burden on the health service and increase quality of life for the patient.

() noted that the temporary suspension by portfolio company () of patient recruitment for one of their clinical studies is not expected to affect the overall timing of clinical data.

PDS issued a statement announcing that the Phase 2 clinical trial led by the National Cancer Institute (NCI), evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers, had paused recruitment due to an issue that is not specific to the trial itself.

NetScientific PLC (AIM:NSCI, FRA:NTK1) said investee company PDS Biotechnology Corporation (NASDAQ:PDSB) has completed enrolment of the first stage of its phase II head and neck cancer clinical trial.

The checkpoint inhibitor naive arm of its VERSATILE-002 study will treat people with recurrent and/or metastatic human papillomavirus (HPV16) form of the disease.